{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:30:09Z","timestamp":1789727409986,"version":"4.0.1"},"reference-count":0,"publisher":"Nepal Health Research Council","issue":"01","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nepal Health Res Counc"],"abstract":"<jats:p>Background: Antimicrobial resistance in Escherichia coli is mostly associated with \u00df-lactamases and carbapenemases enzyme production resulting in treatment challenges. This study was conducted with the aim to detect and characterize antimicrobial resistance in E. coli isolates.\r\nMethods: A cross-sectional study was conducted during 2018-2022, at National Public Health Laboratory where the clinical specimens (24636) received were processed for identification and characterization of antimicrobial resistance following conventional &amp; advanced methods. Antibiotic susceptibility tests were performed by Modified Kirby Bauer disc diffusion and Minimum inhibitory concentrations using VITEK2 compact (Biomeriux). The isolates were tested for extended-spectrum \u03b2-lactamases and Carbapenemase production following Clinical Laboratory Standards Institute guidelines.\r\nResults: Bacterial growth was observed in 9% (2166\/24636) of the specimens, of which 44% (959) were E. coli. Among the 959 E. coli isolates, 320 were reconfirmed with VITEK-MS (Biomeriux). Phenotypic multi-drug resistance was observed in 75% (240\/320) of the isolates with 62% (197\/320) extended-spectrum \u03b2-lactamases, 12% (39\/320) AmpC-\u00df-lactamase, 10% (31\/320) serine carbapenemases and 7% (22\/320) Metallo-\u00df-lactamase while 3% (9\/320) produced three types of enzymes. The extended-spectrum-\u03b2-lactamase producing E. coli were sensitive to Tigecycline (100%), Amikacin (92%), Imipenem (87%), and Meropenem (84%). Carbapenemase producers were sensitive to Tigecycline (100%), with 61% to Amikacin. Extensive-drug resistance was observed in 2% (7\/320) of the isolates, with Colistin resistance in one.\r\nConclusions: The findings highlight alarmingly high antimicrobial resistance in E. coli posing significant challenges in treatment. Early detection of multi-drug resistant isolates in healthcare settings is crucial to combat antimicrobial resistance.\r\nKeywords: \u03b2-lactamase; carbapenemases; extensive-drug resistance; metallo-\u00df-lactamase; multidrug resistance<\/jats:p>","DOI":"10.33314\/jnhrc.v23i01.5067","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:01:19Z","timestamp":1751605279000},"page":"31-41","source":"Crossref","is-referenced-by-count":1,"title":["Multidrug resistant Escherichia coli isolated at  National Public Health Laboratory, Nepal"],"prefix":"10.33314","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-8538","authenticated-orcid":false,"given":"Jyoti","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-3987","authenticated-orcid":false,"given":"Anjana","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-9091","authenticated-orcid":false,"given":"Nisha","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1591-154X","authenticated-orcid":false,"given":"Runa","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-8236","authenticated-orcid":false,"given":"Komal Raj","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-1732","authenticated-orcid":false,"given":"Supriya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-6127","authenticated-orcid":false,"given":"Megha Raj","family":"Banjara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-412X","authenticated-orcid":false,"given":"Prakash","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18778","published-online":{"date-parts":[[2025,6,29]]},"container-title":["Journal of Nepal Health Research Council"],"original-title":[],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:01:28Z","timestamp":1751605288000},"score":1,"resource":{"primary":{"URL":"http:\/\/103.69.126.137\/index.php\/jnhrc\/article\/view\/5067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.33314\/jnhrc.v23i01.5067","relation":{},"ISSN":["1999-6217","1727-5482"],"issn-type":[{"value":"1999-6217","type":"electronic"},{"value":"1727-5482","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}